Commentary on 'Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies' by Sievers et al.

Rissmann Robert; Zuiker Rob

首页> 外文期刊>British Journal of Clinical Pharmacology >Commentary on 'Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies' by Sievers et al.

【24h】

Commentary on 'Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies' by Sievers et al.

机译：“I / II阶段试验的调查员小册子缺乏关于临床前安全性鲁棒性的信息”的评论。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《British Journal of Clinical Pharmacology》 |2021年第7期|共2页
作者
Rissmann Robert; Zuiker Rob;
展开▼
作者单位

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. Study protocol of the Asian XELIRIrnProjecT (AXEPT): a multinational, randomized,rnnon‑inferiority, phase III trial of second‑linernchemotherapy for metastatic colorectal cancer,rncomparing the efficacy and safety of XELIRIrnwith or without bevacizumab versus FOLFIRIrnwith or without bevacizumab [J] . Masahito Kotaka, Hiroshi Matsumoto, Kentaro Yamazaki, 癌症（英文版） . 2016,第012期
2. Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma： a phase II study [J] . Mohamed A. Ebrahim, Hend A. El-Hadaad, Omyma A. Alemam, 中德临床肿瘤学杂志：英文版 . 2010,第008期
3. Commentary on “Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies” by Sievers et al. [J] . Robert Rissmann, Rob Zuiker British journal of clinical pharmacology . 2021,第7期

机译：“I / II阶段试验的调查员小册子缺乏关于临床前安全性鲁棒性的信息”的评论。
4. Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies [J] . S?ren Sievers, Susanne Wieschowski, Daniel Strech British journal of clinical pharmacology . 2021,第7期

机译：I / II阶段试验的调查员小册子缺乏关于临床前安全性研究的鲁棒性的信息
5. Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies [J] . Sievers Soeren, Wieschowski Susanne, Strech Daniel British Journal of Clinical Pharmacology . 2021,第7期

机译：I / II阶段试验的调查员小册子缺乏关于临床前安全性研究的鲁棒性的信息
6. Thermoenhancemental Effects of Adenovirus-mediated p53 (Ad-p53):Preclinical Study and A Phase I Clinical Trial [C] . (missing) Asian congress on hyperthermic oncology . 2002

机译：腺病毒介导P53的热敏效应P53（Ad-P53）：临床前研究和I期临床试验
7. Preclinical pharmacokinetic and tolerance assessment and phase I clinical trial of MU-Gold, a novel chemotherapeutic agent. [D] . Higginbotham, Mary Lynn. 2004

机译：新型化学治疗剂MU-Gold的临床前药代动力学和耐受性评估以及I期临床试验。
8. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial following preclinical studies to ensure safety [O] . Akio Ido, Akihiro Moriuchi, Masatsugu Numata, 2011

机译：重组人肝细胞生长因子（rh-HGF）在暴发性肝炎患者中的安全性和药代动力学：I / II期临床试验经过临床前研究以确保安全性
9. Commentary on “Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies” by Sievers et al. [O] . Robert Rissmann, Rob Zuiker 2021

机译：“I / II阶段试验的调查员小册子缺乏关于临床安全研究鲁棒性的信息”的评论。
10. Phase II Report of Preclinical Intravenous Lethality and Toxicity Study in CD2F1 Mice and Toxicity Study in Beagle Dogs of 2-Fluoro Ara AMP (NSC-312887) [R] . Collins, W. T. , Hiles, R. A. , Fulfs, J. C. , 1983

机译：CD2F1小鼠的临床前静脉致死率和毒性研究的II期报告和2-Fluoro ara amp Beagle犬的毒性研究（NsC-312887）

Commentary on 'Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies' by Sievers et al.

著录项

相似文献

相关主题

期刊订阅